Fortress Biotech (FBIO) vs Polaryx Therapeutics (PLYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Polaryx Therapeutics is the larger company by market cap ($66.3 million vs $64.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | PLYX |
|---|---|---|
| Share price | $1.90 | $1.33 |
| Market cap | $64.11M | $66.30M |
| 1-day change | +7.34% | -11.92% |
| YTD return | -48.09% | — |
| 1-year return | -26.64% | — |
| 5-year return | -95.52% | — |
| P/E ratio (TTM) | 0.83 | — |
| EPS (TTM) | $2.30 | $-0.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $63.26M | — |
| Revenue growth (YoY) | +9.69% | — |
| Net income (latest FY) | $6.82M | $-8.98M |
| Gross margin | 66.92% | — |
| Operating margin | -111.00% | — |
| Net margin | 10.77% | — |
| 52-week high | $4.53 | $48.91 |
| 52-week low | $1.64 | $1.30 |
| Distance from 52-week high | -58.06% | -97.28% |
| Analyst consensus | none | none |
| Avg. price target upside | +163.16% | +463.91% |
| Average volume | 281.49K | 36.42K |
| Shares outstanding | 33.74M | 49.85M |
| Employees | 78 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
FBIO vs PLYX FAQ
Which is bigger, Fortress Biotech or Polaryx Therapeutics?
Polaryx Therapeutics (PLYX) is larger, with a market capitalization of $66.30M compared with $64.11M for Fortress Biotech (FBIO).
Are Fortress Biotech and Polaryx Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.